AXIM Biotech to Present at Rodman & Renshaw 19th Annual Global Investment Conference in New York City

NEW YORK, Sept. 07, 2017 -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company will be featured as a presenting company at the Rodman & Renshaw 19^th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-12, 2017 at the Lotte New York Palace Hotel in New York City.

George Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM, will present a corporate update at the Conference on September 11 at 5:05-5:30pm ET in Kennedy II. AXIM’s management will also be holding one-on-one meetings with investors at the Conference.

The Global Investment Conference, which will feature more than 300 public and private companies from around the world, with over 2,000 attendees, offers investors sector tracks devoted to Biotechnology & Healthcare, Metals & Mining, CleanTech, Technology and Media & Telecommunications.

AXIM’s presentation will be available on the corporate website.

About AXIM^®
AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew Plus™, a CBD-based controlled release chewing gum containing 10mg of hemp-derived CBD, CanChew+ 50™, containing 50 mg of CBD undergoing clinical trials in patients with IBS, and MedChew Rx™, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM^® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). 

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070
[email protected]
www.cmwmedia.com

Investor Relations Contact:
Shiwei Yin, Grayling
[email protected]
P. +1646 284-9474
Lucia Domville, Grayling
[email protected]
P. +1646 284-9416

Corporate Contact Info:
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246

European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227